SQUAWK/NEWS
Menu
Live News EARNINGS ARTICLE H impact

Jim Cramer: Arista Is ‘Terrific,’ Also Likes This Consumer Cyclical Stock

On CNBC’s “ Mad Money Lightning Round,” Jim Cramer said he likes Ross Stores, Inc. (NASDAQ: ROST ). On the earnings front, Ross Stores, on May 21, reported better-than-expected first-quarter financial results and raised its FY26 GAAP EPS guidance above estimates. Ross Stores reported quarterly earnings of $2.02 per share which beat the analyst consensus estimate of $1.68 per share. The company reported quarterly sales of $6.010 billion which beat the analyst consensus estimate of $5.567 billion. Cramer said Hims & Hers Health, Inc. (NYSE: HIMS ) is a “controversial” stock and he prefers to just own Eli Lilly and Company (NYSE: LLY ). According to recent news, a Food and Drug Administration advisory panel voted on July 23 to place the BPC-157 peptide on an allowed pharmacy compounding list. Arista Networks, Inc. (NYSE: ANET ) is “terrific,” Cramer sa...

ANETHIMSLLYROST

On CNBC’s “ Mad Money Lightning Round,” Jim Cramer said he likes Ross Stores, Inc. (NASDAQ: ROST ).

On the earnings front, Ross Stores, on May 21, reported better-than-expected first-quarter financial results and raised its FY26 GAAP EPS guidance above estimates.

Ross Stores reported quarterly earnings of $2.02 per share which beat the analyst consensus estimate of $1.68 per share.

The company reported quarterly sales of $6.010 billion which beat the analyst consensus estimate of $5.567 billion.

Cramer said Hims & Hers Health, Inc. (NYSE: HIMS ) is a “controversial” stock and he prefers to just own Eli Lilly and Company (NYSE: LLY ).

According to recent news, a Food and Drug Administration advisory panel voted on July 23 to place the BPC-157 peptide on an allowed pharmacy compounding list.

Arista Networks, Inc. (NYSE: ANET ) is “terrific,” Cramer said. “I really like Arista, and Arista is not dependent entirely on the data center.

It’s got a lot of things going for it.” Lending support to his choice, Needham analyst Ryan Koontz maintained Arista at a Buy rating on July 22 and raised the price target from $185 to $200.

Price Action: Hims & Hers Health shares fell 3% to settle at $29.32 on Tuesday.

Arista shares slipped 0.6% to close at $169.71 during the session.

Ross Stores shares gained 3.2% to settle at $251.03 on Tuesday.

Photo via Shutterstock